Jasper Therapeutics Reports 2026 Annual Meeting Voting Results

What Happened

• Jasper Therapeutics, Inc. (JSPR) filed an 8-K disclosing results of its 2026 Annual Meeting of Stockholders held July 31, 2026. About 21,121,396 shares (≈75% of 28,009,802 outstanding as of the June 5, 2026 record date) were represented virtually or by proxy. Two Class II directors were elected, PricewaterhouseCoopers LLP was ratified as the company’s independent registered public accounting firm for fiscal 2026, and the advisory vote on executive compensation (say‑on‑pay) was approved.

Key Details

• Shares represented: 21,121,396 shares, ~75% of 28,009,802 outstanding (record date June 5, 2026).
• Director elections (terms to 2029):
  • Judith Shizuru, M.D., Ph.D.: 9,273,875 votes FOR; 419,763 WITHHELD; 11,427,758 broker non‑votes.
  • Tom Wiggans: 9,280,610 votes FOR; 413,028 WITHHELD; 11,427,758 broker non‑votes.
• Auditor ratification (PwC) for fiscal year ending Dec 31, 2026: 20,635,404 FOR; 434,262 AGAINST; 51,730 ABSTENTIONS.
• Advisory vote on named executive officer compensation: 9,016,797 FOR; 604,173 AGAINST; 72,668 ABSTENTIONS; 11,427,758 broker non‑votes.

Why It Matters

• Governance: The re-election of the two Class II directors secures board continuity through the 2029 annual meeting. Vote totals show solid support from voting shareholders for the nominees.
• Auditor confirmation: Ratification of PwC keeps continuity in external financial oversight for fiscal 2026.
• Compensation approval: The advisory say‑on‑pay passed, indicating a majority of voting shareholders backed the company’s executive pay practices (note this vote is non‑binding).
• Investor takeaway: The filing reports routine corporate governance outcomes with substantial shareholder participation (~75%), and no unexpected management or financial changes were disclosed.